changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
LC Bead LUMI™ the first radiopaque embolic bead
LC Bead LUMI™ Revolutionizing the Treatment of HCC
This case was impressive because of the clear visualization of the tumor and the embolized vessels on the post-embolization non-contrast CBCT, in addition to the complete response of the related lesions.
After 4 weeks of follow-up, a complete response on mRECIST was demonstrated with a decrease in tumor size to 0.9 mm.
The radiopaque property of LC Bead LUMI™ allows for accurate needle placement and full lesion ablation. If the lesion cannot be seen on non-contrast CT, there is a possibility that the lesion may not be fully ablated.
Arizona Patients Successfully Receive th...
Recommended Cash Offer for BTG plc by Bo...
BTG plc: Interim Results 2018
One-year results of ACCESS PTS study bri...
OPTALYSE PE Results Presented at Society...
Health Canada approves radiopaque bead f...